Hidehito HORINOUCHI· @HHorinouchi · X·· 1 天前评分70
正文 · 原文
🆙#ESMO26 Proffered Paper I: #LCSM Mets
🔥OptiTROP-Lung06: Sacituzumab Tirumotecan (Sac-TMT) Plus Pembrolizumab (P) Versus Chemotherapy (Chemo) Plus Pembrolizumab (P) as First-Line (1L) Treatment for PD-L1-Negative Advanced Non-Squamous (Nsq) NSCLC: Randomized Phase 3 Study
🎙️Dr. Caicun Zhou
🔢LBA66
🎯Met Primary Endpoint: BICR-PFS 15.0 vs 5.7mo (HR 0.49, p<0.0001; n=455)
🎯OS Immature, Favorable Trend (HR 0.58)
🎯Grade≥3 TEAEs 47.6% vs 60.6%; Grade≥3 Stomatitis 2.2%
☑️NCT06711900
🔗 https://cslide.ctimeetingtech.com/esmo2026/attendee/confcal/show/session/272
@OncoAlert @Larvol @myESMO @IASLC
24 浏览 · 0 赞 · 0 转发 · 0 回复
🆙 #ESMO26 Proffered Paper I: #LCSM Mets 🔥OptiTROP-Lung06: Sacituzumab Tirumotecan (Sac-TMT) Plus Pembrolizumab vs Chemotherapy Plus Pembrolizumab as First-Line Treatment for PD-L1 Negative Advanced Non-Squamous NSCLC 🎙️Dr. Caicun Zhou 🔢LBA66 🎯Met Primary Endpoint: Sac-TMT+Pembrolizumab Significantly Improved PFS vs Chemo+Pembrolizumab, With Positive OS Trend ☑️NCT06711900 🔗 https://cslide.ctimeetingtech.com/esmo2026/attendee/confcal/show/session/272 @OncoAlert @Larvol @myESMO @IASLC在 X 查看被引用的帖子
来源：Hidehito HORINOUCHI · x.com